FDA Approves Rituximab Biosimilar for U.S. Market

The U.S. Food and Drug Administration (FDA) has approved a rituximab biosimilar, developed by Dr. Reddy's Laboratories, for the U.S. market. Fresenius Kabi holds the exclusive commercialization rights for this biosimilar, which is highly similar to Rituxan® and indicated for treating various hematologic malignancies and autoimmune diseases, including non-Hodgkin lymphoma, chronic lymphocytic leukemia, and rheumatoid arthritis. This approval is expected to expand patient access to high-quality, affordable biologic medicines.